Leukemia and Myeloproliferative Disorders
Polycythemia Vera (PV)
1
| Disease Status and/or Stage | Newly diagnosed or relapsed/refractory |
|---|---|
| Protocol Title | The Use of Dasatinib (Sprycel®) in Treating Patients with Polycythemia Vera (PV): A Phase II, Non-Randomized Protocol. |
| PI | Richard Silver, MD |
| Contact | Fernando Adriano, RN 212-746-4882 |
| Key Eligibility | Subjects at least 16 years of age with previous therapies limited to rIFN-alpha, hydroxyurea, anagrelide, and imatinib. Patients must be phlebotemy dependent. |
| Treatment Overview |
Subjects will receive 100 mg oral daily dose of dasatinib. Subjects may continue on study as long as some clinical benefit is shown. |
2
| Disease Status and/or Stage | Newly diagnosed or previously treated |
|---|---|
| Protocol Title | An Open-Label Study of Oral CEP-701 in Patients with Polycythemia Vera or Essential Thrombocytosis with the JAK2 V617F Mutation. |
| PI | Gail Roboz, MD |
| Contact | Mary Crann, RN 212-746-1480 |
| Key Eligibility | Subjects at least 18 years of age are eligible. Patients must have a detectable JAK2 mutation. Subjects with ET must be receiving concomitant hydroxyurea. |
| Treatment Overview | Patients will be administerd a dose of 80 mg bid starting on study day 1 at the baseline visit and will continue receiving treatment until day 126. Patients will participate in an 18-week treatment period with a 2-week follow-up period. Patients who participate in this study may elect to continue receiving treatment with CEP-701 by entering into the extension period after the visit at week 18. |
Last updated: July 30, 2008 |
 |
